Printer Friendly

GLIATECH'S ADCON-L EFFICACIOUS IN PRECLINICAL TESTING; STUDY PUBLISHED IN JOURNAL OF NEUROSURGERY

 CLEVELAND, June 29 /PRNewswire/ -- Gliatech Inc. today announced the publication of a scientific paper in the July issue of Journal of Neurosurgery. The study reports a reduction of postlaminectomy scarring in an animal model through the use of the medical device ADCON-L. Gliatech is currently conducting a pivotal clinical trial of ADCON-L in Europe to evaluate its efficacy in the inhibition of excess scarring following disc surgery.
 "This study further validates that ADCON-L, through a unique cellular mechanism of action, can inhibit the formation of excessive scarring associated with lower back surgery," said Thomas O. Oesterling, Ph.D., president of Gliatech.
 The authors of the study reported that spinal peridural fibrosis (scarring) following a total laminectomy procedure in rabbits was significantly decreased by the application of ADCON-L. In this blinded controlled study, ADCON-L was applied to the operative sites with untreated laminectomy sites serving as controls. The extent of scarring was evaluated by microdissection and microscopic tissue analysis. Dense scar formation and adhesion to surrounding tissue were evident in the untreated sites, whereas the ADCON-L treated sites showed significantly decreased scar formation and adhesions. No adverse effects
were observed. The authors state that these results suggest that ADCON-L may prove beneficial in inhibiting postlaminectomy adhesions and scarring in humans.
 The authors of the report are James T. Robertson, M.D., Albert L. Meric, M.D., F. Curtis Dohan, Jr., M.D., and John B. Schweitzer, M.D., of the Departments of Neurosurgery and Neuropathology at the University of Tennessee, Memphis and Jerome R. Wujek, Ph.D. and Shafik Ahmad, M.D. of Gliatech.
 Earlier this year at the 1993 annual meeting of the American Association of Neurological Surgeons held in Boston, scientists reported reduction in scarring in studies using ADCON-L in both a model of peripheral nerve injury and a model of lower back disc surgery.
 In the peripheral nerve injury study, ADCON-L, was applied to surgically manipulated sciatic nerves of rats and the degree of nerve tethering and compression and scar formation was evaluated seven weeks after surgery. The use of ADCON-L resulted in a statistically significant reduction in both the adherence and fusion of sciatic nerves as compared to untreated animals. Microscopic tissue analysis revealed less formation of dense scar tissue surrounding nerves treated with ADCON-L.
 The authors of the peripheral nerve injury study are Michael Kliot, M.D., John Petersen, Ph.D. and Lisa Russell, Ph.D. of the Department of Neurological Surgery at the University of Washington, Shafik Ahmad, M.D. of Gliatech and Kate Anders of the Seattle VA Medical Center.
 The second study conducted was in a model of lower back disc surgery in which a three-level surgical procedure was performed on adult dogs. ADCON-L was applied at two sites and the third site was left untreated as a control. An eight-week postoperative evaluation indicated a statistically significant reduction of scarring at the ADCON-L treated sites as compared to the untreated site.
 The authors of the discectomy study are James T. Robertson, M.D., and Stephanie L. Einhaus, M.D. of the Department of Neurosurgery at the University of Tennessee, Memphis and Shafik Ahmad, M.D. of Gliatech.
 ADCON-L is the first in a family of products being developed by Gliatech to inhibit excessive scarring following surgery. Other products under development include those intended for abdominal, pelvic, cardiac, tendon and implant surgeries. The next ADCON product to enter clinical trials will be targeted against excess scar formation following tendon surgery.
 Gliatech was formed in 1988 to discover, develop and commercialize therapeutic products based on an understanding of properties of glial cells, a major component of the nervous system.
 -0- 6/29/93
 /CONTACT: Thomas O. Oesterling, Ph.D., president of Gliatech, 216- 831-3200, or Anthony J. Russo of Noonan/Russo Communications, 212-979- 9180, for Gliatech/


CO: Gliatech Inc. ST: Ohio IN: MTC SU:

PS-TS -- NY022 -- 6668 06/29/93 11:43 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:648
Previous Article:CELOX CORPORATION FILES TRADEMARK SUIT AGAINST FORMER ENDOTRONICS
Next Article:PHOENIX LASER SYSTEMS RECEIVES U.S. PATENT FOR OPHTHALMIC WORKSTATION
Topics:


Related Articles
GLIATECH BEGINS PIVOTAL EUROPEAN CLINICAL TRIAL OF PRODUCT TO INHIBIT SCAR TISSUE
GLIATECH INITIATES ADCON CLINICAL TRIALS FOR ADDITIONAL INDICATIONS; STUDIES TO TEST PRODUCT EFFECTIVENESS IN INHIBITING ADHESIONS
GLIATECH BEGINS U.S. CLINICAL TRIAL FOR ADCON-L -- PRODUCT TO INHIBIT SURGICAL ADHESIONS AFTER BACK SURGERY --
GLIATECH AWARDED SBIR GRANT TO DEVELOP ADCON-T/N; RESEARCH TO DEVELOP TENDON ADHESION MODEL
GLIATECH'S ADCON-L CLINICALLY EFFECTIVE
GLIATECH REPORT ON ASSOCIATION BETWEEN SCAR AND PAIN PUBLISHED IN 'NEUROSURGERY'
Gliatech European Clinical Data on Effectiveness of ADCON-L Published in European Spine Journal
Gliatech Receives First Patent for ADCON Surgical Adhesion Technology
Gliatech Receives FDA Approval to Initiate Clinical Trials of ADCON(R)-P
Gliatech Plans $13.6 Million Facility at Chagrin Highlands

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters